Daily cytokine fluctuations, driven by leptin, are associated with fatigue severity in chronic fatigue syndrome: evidence of inflammatory pathology by Elizabeth Ann Stringer et al.
Stringer et al. Journal of Translational Medicine 2013, 11:93
http://www.translational-medicine.com/content/11/1/93RESEARCH Open AccessDaily cytokine fluctuations, driven by leptin, are
associated with fatigue severity in chronic fatigue
syndrome: evidence of inflammatory pathology
Elizabeth Ann Stringer1, Katharine Susanne Baker1, Ian R Carroll1, Jose G Montoya2, Lily Chu5,
Holden T Maecker3 and Jarred W Younger1,4*Abstract
Background: Chronic fatigue syndrome (CFS) is a debilitating disorder characterized by persistent fatigue that is
not alleviated by rest. The lack of a clearly identified underlying mechanism has hindered the development of
effective treatments. Studies have demonstrated elevated levels of inflammatory factors in patients with CFS, but
findings are contradictory across studies and no biomarkers have been consistently supported. Single time-point
approaches potentially overlook important features of CFS, such as fluctuations in fatigue severity. We have
observed that individuals with CFS demonstrate significant day-to-day variability in their fatigue severity.
Methods: Therefore, to complement previous studies, we implemented a novel longitudinal study design to
investigate the role of cytokines in CFS pathophysiology. Ten women meeting the Fukuda diagnostic criteria for
CFS and ten healthy age- and body mass index (BMI)-matched women underwent 25 consecutive days of blood
draws and self-reporting of symptom severity. A 51-plex cytokine panel via Luminex was performed for each of the
500 serum samples collected. Our primary hypothesis was that daily fatigue severity would be significantly
correlated with the inflammatory adipokine leptin, in the women with CFS and not in the healthy control women.
As a post-hoc analysis, a machine learning algorithm using all 51 cytokines was implemented to determine whether
immune factors could distinguish high from low fatigue days.
Results: Self-reported fatigue severity was significantly correlated with leptin levels in six of the participants with
CFS and one healthy control, supporting our primary hypothesis. The machine learning algorithm distinguished
high from low fatigue days in the CFS group with 78.3% accuracy.
Conclusions: Our results support the role of cytokines in the pathophysiology of CFS.
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Chronic fatigue syndrome (CFS) is a debilitating dis-
order characterized by at least six months of persistent
fatigue that is not alleviated by rest [1]. Individuals with
CFS often report additional symptoms such as muscle
pain, joint pain, headaches, poor sleep, inability to con-
centrate, sore throat, swollen lymph nodes, and post-
exertion malaise [2]. The condition affects an estimated* Correspondence: jyounger@stanford.edu
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reproduction in any medium, provided the or42 out of every 10,000 – equating to approximately one
million – individuals in the United States [3]. In addition
to the impact on quality of life, it presents substantial
costs to the economy in both direct medical expendi-
tures and lost work productivity [3]. The majority of di-
agnosed individuals are adult women [4].
The development of effective treatments for CFS has
been hindered by the lack of a clearly identified patho-
physiological mechanism for the disorder. There are no
objective blood tests to confirm a diagnosis, and no well-
accepted targets for intervention. Several studies, however,
have demonstrated abnormal inflammatory processes in
CFS. Cross-sectional analyses (CFS versus healthy control)l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cytokines such as TNF-alpha, IL-1alpha, IL-1beta, and
IL-6 [5,6]. Results, however, are inconsistent across
studies [7], and no potential biomarkers have been
consistently supported by research to advance diagno-
sis or treatment.
One challenge of research to date is that individuals
with CFS exhibit significant day-to-day variability in
their fatigue severity. This within-subject variability may
reduce the sensitivity of cross-sectional studies to con-
sistently identify immune abnormalities in these indivi-
duals [8]. We have therefore tested a within-person,
daily immune monitoring approach for identifying CFS
biomarkers. By measuring immune markers over many
consecutive days, we sought to identify serum analytes
that “track” increases and decreases in fatigue severity.
This intensive longitudinal approach may reveal novel
biomarkers overlooked by traditional cross-sectional
immune studies and unveil novel mechanisms in CFS
pathogenesis. The technique may be particularly useful
in cases where daily symptom variability introduces
statistical noise in cross-sectional data, or when im-
mune factors exist in normal concentrations, but still
drive pathological processes because of sensitized tar-
gets. Our goal with this approach is to identify bio-
markers that facilitate diagnosis and may be targets of
future therapies.
We previously piloted the daily immune monitoring
approach in three women with fibromyalgia (FM) and
co-morbid CFS. The participants were monitored for 25
consecutive days, and their daily serum samples analyzed
for concentrations of 51 different cytokines. Out of the
51 analytes, only leptin was significantly correlated with
day-to-day self-reported fatigue severity in all three
women [9]. Leptin is an analyte of interest because, in
addition to being an appetite-regulatory hormone, the
adipokine is an inflammatory agent that has been linked
to pathological inflammatory fatigue [10,11]. Leptin
provokes the release of proinflammatory cytokines from
many cell types, including centrally acting microglia
[12], and is a mediator of cytokine-induced sickness
behavior [13].
Given the results of our preliminary data, we designed
a study comparing ten women with CFS to ten healthy,
age-, sex- and BMI-matched controls. Participants
underwent 25 consecutive days of blood draws, and
completed reports of fatigue severity twice a day. We
hypothesized that leptin would be associated with daily
fatigue severity in the participants with CFS but not in
healthy controls. As a secondary, exploratory aim, we
also tested the ability of 50 other immune factors to
predict fatigue variability in both groups. To our
knowledge, this is the first study of leptin and its role
in CFS.Methods
Participant selection
Healthy women and women with CFS, meeting the Fukuda
diagnostic criteria case definition [1], were recruited from
an existing, prescreened database maintained by Stanford’s
CFS Research Team. During an initial phone screen we
identified potential participants between the ages of 18 and
62 who were fluent in English, capable of transporting
themselves to Stanford daily, and able to receive daily
venous blood draws, for 25 days in a row. Exclusionary
criteria included untreated or uncontrolled significant
psychological comorbidities, blood or clotting disorders,
rheumatologic disease, autoimmune disease, Lyme’s disease,
elevated viral load, active infection, smoking, pregnancy or
plans to become pregnant, and the use of blood thinning
medications or antibiotics. Because inflammation increases
with age, and circulating leptin increases with BMI, healthy
control participants were age-matched and BMI-matched
to the participants with CFS. During the phone screen, 33
patients were excluded from participation due to conflicts
with daily transportation to Stanford (16), Lyme’s disease
(6), Hashimoto’s disease (3), not meeting diagnostic criteria
(3), resolved symptoms (2), sex (2), and age (1). Twelve
healthy controls were excluded for pain conditions (4), thy-
roid conditions (3), conflicts with daily transportation to
Stanford (2), age- and BMI-matching (2), and smoking (1).
Participants were screened again during a site visit at
Stanford’s Adult and Pediatric Pain Laboratory. Each
participant completed screening questionnaires and blood
tests. The questionnaires included a demographic form,
the Hospital Anxiety and Depression Scale (HADS) [14],
and the Fibromyalgia Assessment Form [15]. A score of
16 or higher on the HADS Depression subscale was exclu-
sionary. Participants were also excluded if the blood tests
showed erythrocyte sedimentation rate (ESR) greater than
60 mm/hr, thyroid stimulating hormone (TSH) outside
the range of 0.4 – 4 mIU/L, C-reactive protein (CRP) over
0.9 mg/dL, positive rheumatoid factor, or positive anti-
nuclear antibody (ANA).
Twelve patients and eleven controls met the study
inclusion/exclusion criteria, and each provided written
informed consent for this study in accordance with a
protocol approved by the Stanford University Insti-
tutional Review Board. One patient withdrew participa-
tion for reasons unrelated to the study, and one for
privacy concerns. One control withdrew participation
due to an unrelated accident affecting her ability to drive
to Stanford for daily blood draws. Results for the twenty
completers are reported. The study was run between
September 2011 and October 2012.
Study design
The study protocol consisted of a two-week observa-
tional baseline period followed by 25 consecutive days of
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were given an Android-based device equipped with soft-
ware (Dooblo’s SurveyToGo, Kefar Sava, Israel) to assess
the severity of their CFS symptoms on a visual analogue
scale (VAS). The primary outcome, daily fatigue severity,
was assessed by asking, “Overall, how severe has your
fatigue been today?” The far left of the scale was
anchored at “no fatigue” and the far right was anchored
at “severe fatigue”. Similar questions about the severity
of muscle and joint pain, as well as the quality of sleep
were included in the assessment. Participants completed
the measures twice per day – once in the morning and
once at night. Following the two-week observational
phase, participants underwent 25 consecutive daily visits
to Stanford’s Clinical and Translational Research Unit
(CTRU) for their blood draws, and continued comple-
ting the symptom severity surveys twice a day throughout
this period. During the CTRU visits, participants’ vital
signs (blood pressure, heart rate, and body temperature)
were also taken to assess general health and to screen for
acute infection.
Blood was drawn by trained phlebotomists or research
nurses with a 23-gauge butterfly needle into two 4 cc clot-
activator tubes. The site of the blood draw was rotated
daily to minimize participant discomfort and maintain
vein integrity. After 30 minutes at room temperature, the
blood samples were centrifuged at 350 × g for 15 minutes,
and the serum was extracted, divided into four cryovials,
and stored in a -80 °C freezer for later testing. For each
participant, CTRU visits were held within a two-hour win-
dow (or narrower) throughout the protocol to control for
known diurnal fluctuations in cytokines [16,17]. Individual
schedule conflicts prevented routine appointments in only
a few cases. If unforeseen events prevented participants
from keeping an appointment (one patient and two
healthy controls missed between one and three appoint-
ments each), a blood draw for each missed appointment
was added to the end of the 25 day protocol so that a total
of 25 blood samples were collected for each of the twenty
participants.
Sample processing
Serum samples were processed by Stanford’s Human
Immune Monitoring Center. Human 51-plex Luminex
kits were purchased from Affymetrix and used according
to the manufacturer’s recommendations, with modifica-
tions as described below. Briefly, samples were mixed
with antibody-linked polystyrene beads on 96-well filter-
bottom plates and incubated at room temperature for
2 hours, followed by overnight incubation at 4°C. Plates
were vacuum filtered and washed twice with wash buffer,
then incubated with biotinylated detection antibody
for 2 hours at room temperature. Samples were then
filtered and washed twice as above and resuspended instreptavidin-PE. After incubation for 40 minutes at room
temperature, two additional vacuum washes were
performed, and the samples resuspended in Reading
Buffer. Each sample was measured in singlet. Plates were
read using a Luminex 200 instrument with a lower bound
of 100 beads per sample per cytokine. Median fluores-
cence intensity (MFI) values were reported for each cyto-
kine, using Masterplex software (Hitashi Corp.), after data
quality control to remove samples with low bead counts
or other technical abnormalities.
Statistical analysis
All data were processed and analyzed in SPSS Statistics 20
(Armonk, NY: IBM Corp) unless otherwise noted. Values
of cytokine MFI and fatigue severity were first subject-
centered using z-score transformation. The z-scores
served two purposes. First, they allowed cytokine levels
and fatigue severity to be plotted on the same scale in
order to visualize trends. Second, they allowed analyses to
be run between subjects, without being adversely affected
by large baseline between-subject variability.
Daily data (cytokines and fatigue) were temporally
smoothed with a 3-day moving average. The moving ave-
rage is a procedure commonly employed with time series
data, to remove high-frequency variability and minimize
the impact of random noise on detecting significant trends
[18]. Temporally smoothed data were used in all analyses
except for cytokine network mapping.
NodeXL [19] was used to construct and depict a
network diagram of fatigue and 51 cytokines, creating a
visual display of the relationships among variables for both
the CFS and control groups. Group bivariate correlations
were fed into a spring-embedded Fruchterman-Reingo
algorithm in NodeXL. Variables (fatigue and cytokines)
are represented by squares or “nodes,” and variables that
are significantly correlated are connected by lines or “vec-
tors.” The p-value was adjusted for multiple comparisons
using a 0.01 false-discovery rate, which yielded a corrected
p < 0.0012 statistical threshold for each of the links
displayed in the network diagram. For visualization in
both diagrams, fatigue and leptin are highlighted in red. In
the CFS diagram, the relationships between leptin and
other cytokines that are statistically significant are also
highlighted by red vertices. The multitude of vertices
within the network diagrams illustrates the degree to
which inflammatory factors fluctuate together.
In a separate analysis, as a post-hoc, proof-of-concept
test, we utilized a machine learning algorithm in Weka
[20] to test the ability of cytokines to distinguish high
from low fatigue days. Our goal was to determine whether
cytokines alone could accurately predict daily fatigue
severity in participants with CFS. Machine learning algo-
rithms use multivariate approaches to achieve greater
sensitivity than massive univariate tests for identifying
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ten participants with CFS, the dataset included the nine
most severe fatigue days and nine least severe fatigue days,
for a total of 180 cases. We used Weka’s LibLINEAR
support vector machine algorithm with a cost function
C = 1 and a 10-fold independent cross-validation.
The model built for the participants with CFS was also
tested on the control group to see if this trained model
could also predict fatigue in healthy individuals. For the
healthy controls, the data were likewise divided into the
nine most severe and nine least severe days, but fatigue
scores that were the same for both high and low fatigue
days were excluded. For example, two participants rated
their fatigue as “0” for each of the 25 days, so their data
were excluded from this analysis. A total of 136 cases
were used for the controls.
Results
Demographics
Twenty women between the ages of 29 and 62 (CFS
mean: 52.9; control mean: 53.0) were included in the pri-
mary analyses. Table 1 presents the basic recommended
[21] demographic and medical inventory for each par-
ticipant with CFS (#1 – 10) and for each of the healthy
controls (#11 – 20). All of the participants classified
themselves as Caucasian except for three of the healthy
controls who self-identified as Asian, African- American,
and Latina. Two CFS participants were employed at the
time of participation, whereas eight of the healthy con-
trols were employed. During the two-week baseline
phase, the mean VAS values for fatigue, muscle pain,
and joint pain were significantly higher in participants
with CFS than in controls, while the controls had higher
sleep quality scores (Table 1).
Four participants with CFS reported an acute onset
and six reported a gradual onset of illness, and the ave-
rage duration of illness was 15 years. Eight women with
CFS also met the criteria for a diagnosis of Fibromyalgia,
based on the recent self-report American College of
Rheumatology criteria [15]. None of the women met
criteria for severe depression based on the HADS
Depression sub-scale, and any co-morbid psychological
conditions were stable and maintained by medication.
Table 1 also includes other co-morbid conditions and medi-
cations for all participants. Individuals with higher BMI
tended to have higher serum leptin concentrations, CFS:
r = 0.614, p = 0.059; controls: r = 0.863, p = 0.001. There
was no significant difference between groups for BMI
(t = -0.784, p = 0.443) or leptin (t = -0.867, p = 0.397).
Main results
Our primary hypothesis was that leptin would predict
daily fatigue severity in patients with CFS but not in
healthy controls. Daily fluctuations in self-reportedfatigue (N = 250) were significantly correlated with daily
leptin levels in participants with CFS, r = 0.303, p < 0.01.
In contrast, healthy control data (N = 250) showed no
correlation between fatigue and leptin, r = -0.010,
p < 0.873. Figure 1 displays the 25-day sequence charts
of all ten participants with CFS, as well as corresponding
scatterplots showing the degree of association between
leptin and fatigue, and Figure 2 for the ten healthy
controls. A significant positive correlation was observed
between leptin and fatigue in six participants with CFS
(Table 2: #’s 1, 2, 4, 5, 6, 9), with r’s ranging between
0.407 and 0.747, and one healthy control (Table 2: #19).
A significant negative correlation was observed in one
individual with CFS (Table 2: #8). Leptin correlations
with fatigue severity scores collected at different times of
day (AM, PM, and mean) for each participant are
displayed in Table 2.
Next, in the CFS group and control group, we exam-
ined relationships between fatigue and all 51 available
cytokines. These analyses were intended to determine
whether analytes other than leptin are important in
predicting daily fluctuations in fatigue. First, bivariate
correlations were computed between all variables and
graphed for the CFS group (Figure 3A) and the control
group (Figure 3B). Of the 51 analytes, only leptin was
directly correlated with fatigue in the CFS group, using
the p-value threshold corrected for multiple comparisons.
Leptin, in turn, was significantly associated with 29 other
cytokines, with the strongest relationships including gran-
ulocyte macrophage colony-stimulating factor (GMCSF),
macrophage colony-stimulating factor (MCSF), transfor-
ming growth factor alpha (TGF-a), interferon-alpha
(IFN-a), interferon-beta (IFN-b), intercellular adhesion
molecule 1 (ICAM1), monocyte-specific chemokine 3
(MCP3), interleukin 6 (IL6), interleukin 10 (IL10), inter-
leukin 12 subunit at p40 (IL12 P40), tumor necrosis factor
beta (TNF-b), TNF-related apoptosis-inducing ligand
(TRAIL), and vascular endothelial growth factor (VEGF).
These analytes were associated with a number of other
analytes, leading to a “nest” of related cytokines. These
tertiary relationships support the overall role of inflamma-
tion in the pathophysiology of fatigue in patients with
CFS. In contrast, no analytes correlated with fatigue in the
control group.
In order to determine how well we could classify days as
high fatigue or low fatigue using only cytokines as pre-
dictors, we used a machine learning approach to build a
predictive model. In the independent validation for the
CFS group, Weka’s LibLINEAR algorithm distinguished
high fatigue from low fatigue days (N = 180) with 78.3%
accuracy. The CFS model correctly identified 77.8% of the
low fatigue days and 78.9% of high fatigue days.
We next applied the CFS-trained model to the control
dataset (N = 136), and the model performed at chance


















1 54 Caucasian $10,000-19,999 Not reported 18 Acute 35 61 50 46
2 53 Caucasian $20,000-29,999 Retired/Disablility 31.6 Acute 15 73 71 70
3 53 Caucasian Not reported Retired 25.2 Gradual 30 80 60 41
4 47 Caucasian less than $10,000 Unemployed 25.9 Acute 9 31 6 50
5 61 Caucasian $10,000-19,999 Unemployed/
Disability
35.7 Gradual 7 50 33 32
6 60 Caucasian $80,000 or more Employed 20.6 Gradual 5 64 49 42
7 51 Caucasian $10,000-19,999 Disability 23.3 Gradual 5 81 25 0
8 29 Caucasian $40,000-49,999 Employed 27.5 Gradual 15 62 63 67
9 55 Caucasian $60,000-69,999 Retired/Disablility 20.4 Acute 10 74 70 48
10 62 Caucasian $30,000-39,99 Not reported 42 Gradual 20 36 25 8
11 57 Caucasian $20,000-29,999 Employed 33.1 NA NA 0 0 0
12 48 Caucasian less than $10,000 Unemployed 23 NA NA 18 23 4
13 51 Caucasian less than $10,000 Employed 21.3 NA NA 30 7 19
14 58 Caucasian less than $10,000 Employed 25.1 NA NA 0 0 0
15 52 Asian Not reported Employed 19.7 NA NA 6 1 0
16 50 Caucasian $50,000-59,999 Employed 20.5 NA NA 0 0 0
17 44 Caucasian $30,000-39,999 Employed 25.5 NA NA 5 12 0
18 47 African
American
$80,000 or more Employed 31.6 NA NA 19 9 1
19 61 Caucasian $40,000-49,999 Retired 24 NA NA 15 0 0






























criteria Co-morbid conditions Medications
1 39 88 6.67 6 Yes Osteoarthritis Aspirin, Levothyroxine
2 52 96 6.78 13 Yes Hypothyroid, High Blood Pressure Alprazolam, Amlodipine, Levothyroxine,
Valganciclovir†, Naproxen, Melatonin, Aspirin,
Estradiol
3 65 76 6.56 6 Yes Degenerate Arthritis, Spinal
Stenosis, Sleep Apnea
Estradiol, Valganciclovir†, Lidocaine





Hydroxytryptophan, St. John's Wort
5 37 94 7.00 10 No Graves Disease/Hypothyroid, Obesity Bupropion, Estradiol, Fenofibrate,
Levothyroxine, Valganciclovir†, Fluoxetine,
Acetaminophen
6 39 90 5.89 11 Yes None None
7 71 89 5.89 3 Yes None Acyclovir††
8 55 NA NA 0 Yes None Topiramate
9 55 NA NA 14 Yes None Bupropion, Controlled-Release Morphine,
Progesterone, Loratadine, Diazepam,
Alprazolam, Estradiol, Sertraline, Zolpidem,
Rizatriptan, Ibuprofen, Ketorolac
10 44 84 6.56 3 No Hypothyroid, Obesity,
High Blood Pressure, ADHD
Olmesartan, Bupropion, Thyroid, Estradiol,
Dextroamphetamine and Amphetamine
11 71 42 2.22 0 No High Blood Pressure Amlodipine, Asprin
12 70 NA NA 1 No None None
13 54 NA NA 2 No None Prozac
14 67 NA NA 3 No None None
15 64 48 1.88 0 No None Proton Pump Inhibitor
16 96 20 1.22 0 No None None
17 77 25 1.77 1 No None None
18 80 28 1.66 2 No Borderline High Blood Pressure, High Cholesterol Zyrtec
19 79 26 1.77 1 No Plantar Fasciitis Loratadine
20 79 22 1.33 1 No None None
Data elements for each of the 20 participants (CFS: #1 – 10, Controls: #11 – 20). Participants self-reported race/ethnicity, income, employment/disability status, height, weight, mode of CFS onset, duration of CFS, co-
morbid conditions, and medications. Fatigue, muscle pain, joint pain, and sleep quality were determined by taking the mean from the two-week baseline period of symptom severity assessments. The HADS [14] and
Fibromyalgia Assessment Form [15] were administered during the screening visit. §Scores are from an existing database maintained by Stanford’s CFS Research Team. †Valganciclovir was prescribed as an experimental


















    leptin
Figure 1 Fatigue and leptin plots for participants with CFS. Left panes: Self-reported fatigue severity (solid blue line) "tracks" with serum
leptin concentration (dotted green line) over the 25-day protocol in six patients with CFS (#'s 1, 2, 4, 5, 6, 9). Right panes: Scatter plots illustrate
the strength of association between self-reported fatigue severity and serum leptin concentration. The data have been Z-score transformed to fit
on the same scale. The mean AM and PM fatigue scores are displayed. Note for #4, the y-axis scale extends to 2.95 instead of 2.5 to accommodate
a data point.
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43.1% of low fatigue days and 68.8% of high fatigue days
in the healthy controls. This suggests that different
factors drive fatigue severity in patients with CFS.
Discussion
We demonstrated that daily fatigue severity is significantly
correlated with daily serum leptin levels in women withCFS but not in healthy controls. Six participants with CFS
and one healthy control demonstrated significant positive
correlations between fatigue and leptin. The findings
confirmed our primary hypothesis that leptin predicts
daily fatigue levels in women with CFS. In a secondary
analysis, we widened the analyses to 50 other cytokines. In
participants with CFS the relationship between immune
factors and fatigue was so strong that we were able to
fatigue 
    leptin
Figure 2 Fatigue and leptin plots for healthy controls. Left panes: Self-reported fatigue severity (solid blue line) "tracks" with serum leptin
concentration (dotted green line) over the 25-day protocol in one healthy control (#19). Right panes: Scatter plots illustrate the strength of
association between self-reported fatigue severity and serum leptin concentration. The data have been Z-score transformed to fit on the same
scale. The mean AM and PM fatigue scores are displayed.
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78.3% accuracy, using only cytokines as predictors.
Additionally, when this CFS-trained model was applied to
the control dataset, the model performed at a chance level.
The results support a role of inflammation in CFS
pathology.
In the search to uncover CFS pathophysiological mecha-
nisms, considerable effort has been directed at examining
dysregulation of the immune system. Of particular interestare cytokines that can drive sickness behaviors such as
fatigue and hypersensitivity to pain [22,23]. While many
studies have identified potential cytokine differences
between individuals with CFS and healthy controls, results
have been contradictory [7]. The lack of consistent results
across studies may be due partially to the use of cross-
sectional designs in a condition driven by atypical, low-
level inflammatory processes [8]. We have observed that
CFS symptom severity can change drastically in a short
Table 2 Outcome measures
Pearson correlation coefficient with Leptin
(*p<0.05; **p<0.01)
Participant AM fatigue PM fatigue Mean fatigue
1 0.38 0.696** 0.582**
2 0.32 0.676** 0.535**
3 0.02 −0.047 −0.015
4 0.304 0.451* 0.407*
5 0.588** 0.749** 0.731**
6 0.583** 0.434* 0.747**
7 −0.173 0.005 −0.097
8 −0.405 * 0.034 −0.516**
9 0.591** 0.250 0.497*
10 −0.015 −0.205 −0.173
11 0.298 −0.237 −0.226
12 0.095 0.238 0.276
13 −0.416* 0.545* −0.056
14 NA NA NA
15 0.069 0.222 0.176
16 NA NA NA
17 −0.402* −0.241* −0.342
18 −0.210 −0.327 −0.268
19 0.262 0.539** 0.429*
20 −0.363 −0.412* −0.386
Outcome measures for each of the 20 participants (CFS: #1 – 10, Controls: #11 – 20).
The correlations (r-value) between serum leptin levels and daily (AM, PM, and
mean) fatigue severity are reported, *p<0.05, **p<0.01.
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days. Such daily variability may blur the distinction
between cases and controls in cross-sectional studies. We
therefore propose a novel approach of daily immune
monitoring to complement conventional cross-sectional
studies. By capturing immune fluctuations every day, we
can detect immune-fatigue relationships even when
cytokine concentrations are highly variable over time, or
when cytokines are driving symptoms at “normal” concen-
trations because downstream targets have been sensitized.
In our analyses of participants with CFS, the strongest
relationship between cytokines and fatigue involved
leptin. Although leptin is most broadly recognized as a
pleiotropic peptide hormone secreted by adipocytes for
regulating energy homeostasis, it is also an adipokine that
modulates immune responses. Administration of endo-
toxin in both rodents and humans leads to increased gene
expression for leptin and increased serum leptin levels
[24,25]. Likewise, leptin administration affects both the
adaptive and innate immune systems [26], increasing the
release of the proinflammatory cytokines TNF-alpha, IL-2,
IL-6, and IL-12 [27,28]. Multiple studies have demon-
strated elevated levels of circulating leptin in chronicinflammatory conditions [29,30]. Serum leptin concentra-
tions are also associated with fatigue severity in patients
with chronic hepatitis C and irritable bowel syndrome
[10,11].
The relationship we observed between leptin and
fatigue existed even though leptin levels were not abnor-
mally elevated, and there was no statistical difference in
leptin values between the CFS and control groups. Most
of the body’s leptin is secreted from white adipose tissue,
and consequently, circulating leptin levels should be
correlated with BMI. Leptin also demonstrates regular
diurnal fluctuations that can change concentrations by
over 50% in the course of a day [16,17]. To mitigate the
effect of diurnal rhythms on our results, we asked that
participants complete their laboratory session at the
same time each day, within a two-hour window. The
percent change of leptin we observed over the study
period was within the expected diurnal fluctuation
range. The results suggest that absolute leptin levels
were not abnormal, and therefore the relationship with
symptom severity might only be observed with a longi-
tudinal design.
While we believe the daily immune monitoring
approach is a strong complement to cross-sectional
studies, there are still limitations with our small sample
size. We note that FM and CFS are frequently co-
morbid. Future studies of larger populations would allow
us to determine the degree of overlap between these
conditions. A larger study would also allow us to study
lagged effects and examine possible pathways of causa-
lity. Our network analyses, using a simple massive
univariate analysis approach, revealed that leptin was the
only cytokine to covary significantly with fatigue in
participants with CFS, while there was no relationship
between fatigue and leptin (or any other cytokine tested)
in the healthy controls. Even though leptin is reported to
modulate other cytokines, specifically TNF-alpha, IL-2,
IL-6, and IL-12 [28], we did not observe relationships
between those cytokines and fatigue variability. Future
work should address whether leptin is the causal factor
in fatigue severity, perhaps by administration of recom-
binant methionyl human leptin. Future analyses may
also use time-lagged variables and techniques such as
Granger Causality Modeling to better determine causal
pathways.
Conclusions
These results add to the literature supporting a role of
cytokines in CFS pathophysiology. We have identified a
subset of women with CFS who demonstrate a strong
correlation between leptin levels and fatigue severity.
Future work should explore both the role of leptin, and
of daily cytokine fluctuations in general, in driving CFS
disease severity. Ultimately, these analysis techniques
A)
B)
Figure 3 Network diagrams for A) participants with CFS and B) healthy controls. A network diagram of fatigue and 51 cytokines was
constructed in NodeXL. All participants were included in the analysis. Fatigue and leptin are highlighted in red, and variables with significant
correlations with fatigue and leptin are represented by red edges (A). The network diagram was thresholded at p < 0.0012, false discovery rate
controlled for multiple comparisons.
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